Aclaris Therapeutics, Inc. (ACRS)

NASDAQ: ACRS · IEX Real-Time Price · USD

1.140

-0.010 (-0.87%)

At close: Jul 2, 2024, 4:00 PM

1.190

+0.050 (4.39%)

After-hours: Jul 2, 2024, 7:52 PM EDT

Aclaris Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Revenue	31.25	29.75	6.76	6.48	4.23	Upgrade
Revenue Growth (YoY)	5.03%	340.05%	4.30%	53.35%	-31.28%	Upgrade
Cost of Revenue	18.08	11.96	4.71	5.13	4.06	Upgrade
Gross Profit	13.17	17.79	2.05	1.35	0.17	Upgrade
Selling, General & Admin	32.41	25.13	23.62	20.53	27.83	Upgrade
Research & Development	98.38	77.81	43.81	29.34	64.17	Upgrade
Other Operating Expenses	6.63	0	0	0	18.5	Upgrade
Operating Expenses	137.43	102.95	67.43	49.87	110.5	Upgrade
Operating Income	-124.26	-85.15	-65.38	-48.52	-110.32	Upgrade
Other Expense / Income	-35.41	1.75	25.48	2.68	51.03	Upgrade
Pretax Income	-88.85	-86.91	-90.87	-51.2	-161.35	Upgrade
Income Tax	-0.37	0	0	-0.18	0	Upgrade
Net Income	-88.48	-86.91	-90.87	-51.02	-161.35	Upgrade
Shares Outstanding (Basic)	70	65	57	43	41	Upgrade
Shares Outstanding (Diluted)	70	65	57	43	41	Upgrade
Shares Change	7.05%	14.95%	33.36%	2.94%	25.57%	Upgrade
EPS (Basic)	-1.27	-1.33	-1.60	-1.20	-3.90	Upgrade
EPS (Diluted)	-1.27	-1.33	-1.60	-1.20	-3.90	Upgrade
Free Cash Flow	-79.63	-68.17	-52.44	-39.09	-98.06	Upgrade
Free Cash Flow Per Share	-1.14	-1.04	-0.92	-0.92	-2.37	Upgrade
Gross Margin	42.14%	59.80%	30.29%	20.81%	4.07%	Upgrade
Operating Margin	-397.64%	-286.21%	-967.08%	-748.52%	-2609.98%	Upgrade
Profit Margin	-283.15%	-292.11%	-1343.96%	-787.03%	-3817.22%	Upgrade
Free Cash Flow Margin	-254.84%	-229.13%	-775.65%	-602.99%	-2319.80%	Upgrade
EBITDA	-87.99	-86.11	-89.94	-49.87	-154.95	Upgrade
EBITDA Margin	-281.56%	-289.43%	-1330.31%	-769.41%	-3665.60%	Upgrade
Depreciation & Amortization	0.86	0.8	0.92	1.32	6.41	Upgrade
EBIT	-88.85	-86.91	-90.87	-51.2	-161.35	Upgrade
EBIT Margin	-284.32%	-292.11%	-1343.96%	-789.83%	-3817.22%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).